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Abstract. 
While the management of myeloma and light chain deposition disease (“MM”) has 
changed considerably in the last decade, it is unknown how the burden of associated end-
stage renal (ESRD) has evolved.  
Methods. 
United States Renal Data System data (n = 1,048,683) for the years 2001-2010 were used 
to calculate incidence rates and outcomes of MM (n = 12,704, 1.3%).  
Results. 
Compared to 2001-2002, standardized incidence ratios declined to 0.8 for 2009-2010. 
Characteristics of MM patients included older age (≥ 65, 63.7% vs. 43.7%) and white 
race (76.3% vs. 65.1%). Multiple myeloma was associated with a greater likelihood of 
death (adjusted hazards ratio [AHR] 2.3) and a lower likelihood of listing for (AHR 0.2) 
a kidney transplant. While hazards ratios for listing increased over time (AHR 1.06 for 
2009-2010 Vs. 2001-2002), those for transplant and death did not (AHRs 0.6 and 0.9, 
respectively). Regional variation in outcomes was apparent, as patients in the South were 
more likely to die (AHR 1.04 Vs. the Northeast), and more likely to not be listed (AHR 
2.4) nor receive a transplant (AHR 2.9).  
Conclusions. 
While ESRD due to MM has declined in the United States, outcomes on dialysis remain 
poor and exhibit substantial geographic variation. 
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Introduction. 
Multiple myeloma and light chain deposition disease (collectively referred to as 
“MM”) belong to a family of plasma cell dyscrasias associated with significant renal 
involvement; having been reported to be the most common malignancy leading to 
ESRD1. Reduction in production of light chains is the hallmark of therapy (related to 
renal recovery) and even in the setting of aggressive therapy, there is a high rate of 
progression to ESRD, with recovery occurring in only 15 – 20% of patients2. Kidney 
disease is a common feature of MM with ominous prognostic implications3, 4. Novel 
treatments such as lenalidomide, thalidomide, bortezomib, and use of autologous stem 
cell transplantation offer hope and survival prospects for patients with MM have 
improved in recent years5-11. In contrast, it is unknown how the burden of ESRD due to 
MM has evolved. Hence, we sought to describe the clinical and epidemiologic trends of 
ESRD due to MM in the US from 2000-2010. 
 
Results. 
The overall incidence rate of dialysis requiring ESRD (Table 1, Figure 1) due to 
MM was 4.5 per million in 2001-2002. This rate remained largely unchanged until later 
biennia, significantly decreasing in 2007-2008 (4.1) and further decreased in 2009-2010 
(3.9). In each biennium, higher incidence rates were associated with older age, male 
gender, African American race, and residence in both the Northeast and Midwest. 
Standardized incidence ratios (SIR) decreased over time, both in the overall population 
(SIR 0.8 for 2009-2010 vs. 2001-2002) and in all subgroups examined except those < 45 
years old, Hispanic ethnicity, and residence in the West.  
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 Table 2 compares characteristics of patients initiating maintenance dialysis 
therapy due to MM versus non-MM causing ESRD. Associations with AOR >1.5 
(adjusted for age, sex, race/ethnicity) included age 40-64 years (AOR 5.13), age 65 years 
or older (AOR 6.95), white race (AOR 1.58), presence of graft (AOR 1.66) or catheter 
(AOR 4.61) at dialysis initiation, and pre-dialysis nephrology care of < 12 months (AOR 
3.18). Characteristics associated with an AOR < 0.66 (the reciprocal of 1.5) include 
Hispanic ethnicity (0.42), ischemic heart disease (AOR 0.39) and diabetes mellitus (AOR 
0.2), peritoneal dialysis (AOR 0.47), GFR > 15 ml/min/1.73m2 (AOR 0.4), BMI > 30 
kg/m2 (AOR 0.52), and a higher serum hemoglobin (AOR 0.61; 9-10.9 g/dL, AOR 0.38; 
≥ 11 g/dL).  
 Figure 2 demonstrates outcomes rates in subjects with ESRD due to MM 
compared to those remaining with ESRD, matched for age, sex, race/ethnicity, and year 
of dialysis initiation. Mortality rates were higher in all subgroups of patients with MM 
(overall rate of 58.1 vs. 25.8, ratio 2.25). Ratios were similar across most subgroups, with 
the highest ratio observed in those < 40 years (AOR 3.38). Similar mortality rates were 
seen in the 5 biennia. Subjects with MM were 4.5 times less likely to be listed for kidney 
transplantation and 4.3 times less likely to receive a transplant, with the least likelihood 
of both listing (AOR 0.07) and receipt of transplant (AOR 0.1) observed in 2009-2010. 
Likelihood of listing for transplant appeared to decrease over time, with the lowest 
regional rates of transplant listing and receipt of kidney transplant associated with 
regional residence in both the West (AOR 0.19 for listing; AOR 0.18 for transplant 
received) and the South (AOR 0.15 for listing; AOR 0.125 for transplant received). 
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Outcomes among patients with ESRD due to MM are shown in Table 3. The 
highest risk ratios (AOR > 1.5) for mortality were observed in age 40 – 64 years (AHR 
2.15 vs. age < 40 years), age ≥ 65 years (AHR 3.92), use of catheter (AHR 2.12 Vs. 
fistula), and serum albumin < 3.5 g/dL (1.57 vs. albumin > 4 g/dL). Likelihood of listing 
decreased with age (AHR 0.27, 40-64 yrs; AHR 0.05, > 65 yrs), catheter use (AHR 0.29), 
dialysis ≤ 12 months (AHR 0.35) and residence in the South (AHR 0.42). Factors 
associated with increased likelihood of listing include peritoneal dialysis (AHR 2.63) and 
increasing serum hemoglobin levels (AHR 1.74, Hgb 9-10.9g/dL; AHR 2.34, Hgb ≥ 11 
g/dL). Characteristics associated with increased likelihood of transplantation largely 
paralleled that of listing for transplantation peritoneal dialysis (AHR 2.13), and 
hemoglobin ≥ 11 g/dL (AHR 2.41). Those associated with decreased likelihood of 
transplantation included increasing age (AHR 0.29, 40-64 years; AHR 0.04, ≥ 65 years), 
catheter (AHR 0.26), dialysis duration ≤ 12 months (AHR 0.35), and residence in the 
South and West regions (AHR 0.35 and AHR 0.52, respectively).  
Approximately 1.5% of patients with ESRD due to MM underwent listing for 
transplantation and only 0.9% (n = 109) received transplant; 61.5% were male, 83.5% 
were white, 84% had been on dialysis > 12 months, and 59.4% received live donor 
transplants (Table 4). Over time, the number of total transplants performed increased, 
nearly doubling by 2009-2010 (23.9% Vs. 11.9%). Graft loss and death after 1 year 
occurred in 4.6% and 6.4%, respectively. Graft loss occurred in 13.8% and death in 
20.2% of those transplanted with MM. Approximately 41.7% of the transplants occurred 
with residence in the Midwest and 25.9% occurred in the Northeast.  
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Methods. 
The main objectives of this study were to describe trends in biannual incidence 
rates between 2001 and 2010, the main objective, with and without considering trends in 
the demographic characteristics of the US population, determine incidence rate trends in 
subgroups of the US population defined by age, sex, and race/ethnicity, and determine 
rates and risk factors for the following clinical outcomes occurring after initiation of 
maintenance dialysis for ESRD from MM: death, wait-listing for kidney transplant, and 
receipt of kidney transplant.  
This was a retrospective study using United States Renal Data System (USRDS) 
standard analysis files to study US patients who initiated dialysis between 2001 and 2010 
(n = 1,048,683). Patient characteristics at initiation of were obtained from the USRDS 
Medical Evidence Report (Centers for Medicare & Medicaid [CMS] form CMS-2728, 
with corresponding data in the Medevid95 and Medevid05 files). This form changed in 
2005; additional data fields gather information about vascular access used at 
hemodialysis initiation and duration of pre dialysis nephrology care. Of note, the options 
for designating primary cause of ESRD remained unchanged. Cases of MM and LCDD 
for this study listed primary cause of ESRD as “multiple myeloma” and “light chain 
deposition disease”. Dates of death and first kidney transplant were obtained from the 
Patients file, and first listing for renal transplant from the Waitlist_ki and Waitlist_kp 
files. US census data were used to determine general population denominators for each 
year studied, with age in 5-year increments and race/ethnicity classified as non-Hispanic 
white, non-Hispanic black, Hispanic, and other. The Poisson distribution was used to 
calculate incidence rates.  
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For the calculation of standardized incidence ratios, expected incidence rates were 
calculated by applying incidence rates in 2000 for each of the possible combinations of 
age (21 subgroups), sex (2 subgroups), and race-ethnicity (4 subgroups) to the 
corresponding subgroup of the US population for each year 2001 to 2010. Chi-square 
analysis and logistic regression, respectively, were used for comparisons of patients with 
and without MM at dialysis initiation. Cox regression was used to calculate hazards ratios 
for outcomes after initiation of dialysis, with follow-up extending to June 30, 2011. 
Graphical comparison of survival among patients with and without MM was performed 
after matching each MM patient with a non-MM patient according to the following 
variables: year and quarter of dialysis initiation, age (in 1-year increments), sex, race, and 
ethnicity.  SAS, v9.1.3 (Cary, North Carolina) was used for data analysis. 
 
Discussion. 
While European studies have demonstrated an increase in incidence of ESRD due 
to MM of 0.7 to 2.52 per million people from 1986 to 2005, we have shown a significant 
decrease in the standardized incidence rates and ratios of patients initiating dialysis due to 
MM in the US, particularly in the last two biennia of the observation13. The majority of 
cases occurred in those aged ≥ 65 years and reduced incidence ratios were seen in nearly 
all subgroups examined with few exceptions. Given that most patients with MM are 
diagnosed at age > 65 years or older, we demonstrate a positive association of age with 
mortality, with its greatest effect in those ≥ 65 years (AHR 3.92)14. There appeared to be 
no change with residence in the West and a possible increase in those patients < 45 years 
of age, fewer women reaching ESRD in recent years (2006-2010 vs. 2001-2005; 41.4% 
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vs. 46.2%) and an overall increase in those initiating dialysis at a GFR > 15 ml/min2 
(4.3% vs. 7.2%). As expected, overall incidence rates of disease remained lowest in the 
youngest subgroup of patients.  
Those whom were transplanted were more likely to be from the most earlier 
biennia, utilize a fistula for dialysis, be under the care of a Nephrologist > 12 months, and 
less likely to be from a Southern region. These effects likely reflected combination of 
access and care delivery, as well as a possible performance status effect yielding differing 
treatments15. As this analysis was limited in its ability to detect whether these findings are 
directly related to advances in therapy such as changes in standard chemotherapeutic 
protocols, introduction of proteasome inhibitors, and variable dialysis as modalities, 
providers should be cautiously optimistic.10, 11, 16-18.  
Transplantation in the setting of MM is an area with surprisingly few studies and 
remains a controversial topic given the nature and survival with disease, recurrence, and 
risk of adverse outcome. In one series of 9 patients with myeloma cast nephropathy, 
survival reports yielded a wide range of 14 to 114 months19. We demonstrate that only 
0.9% (n = 109) of patients in our analysis underwent transplantation over the 10-year 
follow up period, a number slightly lower than the 1.4% observed in European 
registries20. Previous experience has demonstrated that approximately 30% of kidney 
transplants performed in the setting of MM were received from a live donor, whereas 
60% of transplants were received from a living donor in our analysis13. We found that 
mortality remained significantly higher (AHR 2.25) and transplant listing rates were 
lower in patients with ESRD due to MM in comparison to age-, race- and gender-
matched controls in nearly all subgroups. Our findings demonstrate similar graft survival 
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between groups at one year (MM versus remaining ESRD; 11.4% vs. 13.6%), however 
death occurred in nearly twice as many patients (20.2% vs. 11.8%).  
There several important limitations to our study, many of which arise from use of 
retrospective registry-based data, lack of definitive pathology, and variables with known 
prognostic implications, including free light chain and β2 microglobulin level21, 22. 
Additional clinical information such as performance status and intensity of 
chemotherapy, are not known. Regardless, there are a number of strengths including the 
use of the large size and representative population of interest. This study provides 
important insight in to the landscape and care delivery afforded to patients with ESRD. 
Future studies lie within the identification of clinical parameters and patient variables that 
help clinicians stratify patients whom are appropriate for transplantation. 
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Table 1. Incidence Rates and Standardized Incidence Ratios of Dialysis-Requiring ESRD Due to 
MM and Other Causes in the US, 2001-2010. 
  Biennium 
 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010 
 Population Size, Mean 
 286,297,074 291,456,616 296,948,256 302,662,587 308,060,609 
  Cases 
 2,558 2,518 2,696 2,511 2,421 
 Incidence Rate, Per Million Per Year 
All 4.5 (0.1)a 4.3 (0.1)a 4.5 (0.1)a 4.1 (0.1)a 3.9 (0.1)b 
Age, years      
  0-44 0.2 (0)a 0.2 (0)a 0.3 (0)a 0.2 (0)a 0.2 (0)a 
  45-64 5.8 (0.2)a 6 (0.2)a 6.2 (0.2)a 5.4 (0.2)a 5.2 (0.2)a 
  ≥ 65 24.3 (0.6)a 22.4 (0.6)a 22.7 (0.6)a 20.6 (0.5)c 18.7 (0.5)c 
Sex      
  Male 4.8 (0.1)a 4.7 (0.1)a 5.2 (0.1)a 5 (0.1)a 4.7 (0.1)a 
  Female 4.1 (0.1)a 4 (0.1)a 3.9 (0.1)a 3.3 (0.1)c 3.2 (0.1)c 
Race/Ethnicity      
  Non-Hispanic 
white 
4.7 (0.1)a 4.6 (0.1)a 4.9 (0.1)a 4.4 (0.1)a 4.2 (0.1)a 
  Non-Hispanic 
black 
7.3 (0.3)a 7.2 (0.3)a 7.7 (0.3)a 6.8 (0.3)a 6.8 (0.3)a 
  Hispanic 1.7 (0.1)a 1.8 (0.1)a 2 (0.2)a 2 (0.1)a 1.7 (0.1)a 
  Other 1.9 (0.2)a 1.8 (0.2)a 1.2 (0.2)a 1.7 (0.2)a 1.5 (0.2)a 
Region      
  Northeast 6.9 (0.3) 6.7 (0.3) 6.7 (0.3) 6 (0.3) 5.7 (0.3)a 
  Midwest 5.3 (0.2) 4.5 (0.2) 5 (0.2) 5.2 (0.2) 4.6 (0.2) 
  South 4.3 (0.1) 4.4 (0.1) 4.7 (0.1) 4 (0.1) 3.8 (0.1) 
  West 4.2 (0.2) 4.5 (0.2) 4.6 (0.2) 4.4 (0.2) 4.3 (0.2) 
 Standardized Incidence Ratios 
All 1 (Ref) 0.95 (0.02) 0.98 (0.02) 0.87 
(0.02)00 
0.8 (0.02)00 
Age,years      
  0-44 1 (Ref) 0.92 (0.11) 1.44 (0.14) 1.24 (0.13) 1.15 (0.13) 
  45-64 1 (Ref) 1.01 (0.04) 1.03 (0.03) 0.89 (0.03) 0.83 (0.03)b 
  ≥ 65 1 (Ref) 0.92 (0.02) 0.93 (0.02) 0.85 (0.02)b 0.78 (0.02)c 
Sex      
  Male 1 (Ref) 0.94 (0.03) 1.03 (0.03) 0.97 (0.02) 0.87 (0.02)b 
  Female 1 (Ref) 0.96 (0.03) 0.92 (0.03) 0.76 (0.02)c 0.72 (0.02)c 
Race/Ethnicity      
  Non-Hispanic 
white 
1 (Ref) 0.94 (0.02) 0.98 (0.02) 0.87 (0.02)b 0.8 (0.02)c 
  Non-Hispanic 
black 
1 (Ref) 0.96 (0.04) 1 (0.04) 0.84 (0.04)a 0.81 (0.04)a 
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  Hispanic 1 (Ref) 1.05 (0.09) 1.13 (0.09) 1.1 (0.08) 0.9 (0.07) 
  Other 1 (Ref) 0.93 (0.11) 0.59 (0.09)a 0.83 (0.1) 0.68 (0.08) 
Region      
  Northeast 1 (Ref) 0.97 (0.04) 0.97 (0.04) 0.84 (0.04)a 0.78 (0.03)b 
  Midwest 1 (Ref) 0.85 (0.04)a 0.92 (0.04) 0.92 (0.04) 0.78 (0.03)b 
  South 1 (Ref) 1.02 (0.03) 1.06 (0.03) 0.89 (0.03) 0.82 (0.03)b 
  West 1 (Ref) 1.1 (0.05) 1.12 (0.05) 1.03 (0.05) 0.98 (0.05) 
Note: Parameter estimates are reported with standard errors in parentheses. Standardized 
incidence ratios were calculated by applying rates for 2001-2002 to other biennia. P ≥ 0.05 
unless otherwise indicated. 
a 0.01 ≤ P value (vs. 2000) < 0.05.  
b 0.001 ≤ P value (vs. 2000) < 0.01.  
c P value (vs. 2000) ≤ 0.001.
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Table 2. Baseline Characteristics of Subjects at Initiation of Maintenance Dialysis due Multiple Myeloma.  
    All Patients (n = 1,048,683) 
Patients with MM or LCDD (n = 
12,704) 
    MM or 
LCDD 
No MM or 
LCDD 
AOR MM or 
LCDD 
AOR 2006-2010 Vs. 2001-2005 
n  12,704 1,035,979   
Renal Disease   Multiple Myeloma 100 0   
   Diabetes 0 45.8   
   Hypertension 0 28.5   
   Other 0 25.7   
Year of first dialysis   2001-2002 20.1 18.4 1(Ref)  
 
  2003-2004 19.8 19.3 0.94 (0.89-1)  
 
  2005-2006 21.2 20.2 0.96 (0.91-1.01)  
 
  2007-2008 19.8 20.7 0.88 (0.83-0.93)  
 
  2009-2010 19.1 21.5 0.82 (0.77-0.86)  
Age, yrs.   < 40 1.4 8.9 1(Ref) 1(Ref) 
 
  40-64 35 41.5 5.13 (4.41-5.98) 0.69 (0.51-0.95) 
 
  ≥ 65 63.6 49.6 6.95 (5.97-8.09) 0.63 (0.46-0.86) 
Female Sex Vs. Male 43.8 44.5 0.98 (0.95-1.02) 0.82 (0.77-0.88) 
Race   White 76.4 65.1 1(Ref) 1(Ref)a 
 
  Black 20.8 28.9 0.63 (0.61-0.66) 1.06 (0.97-1.15) 
 
  Other 2.8 6 0.42 (0.38-0.47) 0.96 (0.78-1.19) 
Hispanic ethnicity Yes Vs. No 6.4 13.6 0.42 (0.39-0.46) 1.35 (1.17-1.56) 
Ischemic Heart Disease Yes Vs. No 13.9 24 0.39 (0.37-0.41) 0.86 (0.77-0.95) 
Diabetes Yes Vs. No 17.5 52.9 0.2 (0.19-0.21) 1.26 (1.15-1.38) 
Peritoneal Dialysis Vs. Hemodialysis 3.1 6.8 0.47 (0.43-0.52) 0.77 (0.63-0.95) 
Hemodialysis access   Fistula 3.6 13.9 1(Ref) 1(Ref)a 
 
  Graft 1.5 3.6 1.66 (1.32-2.09) 0.53 (0.28-1.03) 
 
  Catheter 94.9 82.4 4.61 (4.07-5.23) 0.81 (0.53-1.23) 
Prior nephrology care  ≤ 
12 mo. 
Vs. > 12 mo. 90.4 76.3 3.18 (2.94-3.44) 0.84 (0.65-1.08) 
 GFR > 15 ml/min/1.73 Vs.  ≤ 15 5.7 12.3 0.4 (0.37-0.43) 1.67 (1.43-1.96) 
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m2 
Body mass index, kg/m2   18.5-24.9 42.6 33.4 1(Ref) 1(Ref) 
 
  < 18.5 5 4.3 0.94 (0.86-1.02) 0.8 (0.67-0.95) 
 
  25-29.9 31.1 28.4 0.87 (0.83-0.9) 1.15 (1.06-1.25) 
 
  ≥ 30 21.3 33.8 0.52 (0.5-0.55) 1.55 (1.41-1.7) 
Albumin, g/dL   ≥ 4.0 10.4 11.6 1(Ref) 1(Ref)a 
 
  3.5-3.9 18.4 22.4 0.88 (0.81-0.95) 1.02 (0.87-1.19) 
 
  < 3.5 71.2 66.1 1.2 (1.12-1.28) 0.92 (0.8-1.05) 
Hemoglobin, g/dL   < 9 36.3 26 1(Ref) 1(Ref) 
 
  9-10.9 46.7 47.2 0.61 (0.59-0.64) 1.01 (0.93-1.09) 
 
  ≥ 11 17 26.8 0.38 (0.36-0.4) 0.7 (0.63-0.78) 
Region   Northeast 22.2 17.9 1(Ref) 1(Ref)a 
 
  Midwest 23.5 21.6 0.86 (0.82-0.91) 1.13 (1.02-1.26) 
 
  South 36 40.4 0.83 (0.79-0.87) 1.07 (0.97-1.18) 
 
  West 18.2 20.1 0.9 (0.85-0.95) 1.1 (0.99-1.24) 
Note: Parameter estimates are presented as column percentages or odds ratios, with 95% confidence intervals in parentheses. Reflecting 
the fact that 2005 was the first complete year in which data fields for pre dialysis vascular access for hemodialysis and pre dialysis 
nephrology care were included in the Medical Evidence Report, the denominators for these variables consisted of patients initiating 
dialysis 2005-2010.  
P < 0.05 for statistical comparisons, unless otherwise indicated.  
Missing data were as follows: GFR, n =0.6%; BMI, n = 1.4%; Hemoglobin, n = 8.4%; Albumin, n = 24.7%, Region n = 1.8%  
BMI, body mass index; GFR, glomerular filtration rate.      
aP ≥ 0.05. 
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Table 3. Outcomes According to Presence or Absence of Multiple Myeloma (n = 1,048,683) 
    All Patients (n = 1,048,683) 
  Death Transplant Listing Transplanted 
  57.8 (23.6 at 1 Year) 17.3 (10.5 at 1 Year) 9 (2.6 at 1 Year) 
  Characteristics Rate AHR, Death Rate AHR, Listing Rate AHR, Non-
Transplant 
Multiple 
Myeloma 
No 19.7 (0) 1 (Ref) 6.5 (0) 1 (Ref) 3.5 (0) 1 (Ref) 
 
Yes 57.9 (0.6) 2.3 (2.3-2.4) 1 (0.1) 0.2 (0.2-0.2) 0.6 (0.1) 0.2 (0.2-0.2) 
 Patients with MM (n = 12,704) 
  Death Transplant Listing Transplanted 
  82.9 (55.8 at 1 year) 1.5 (0.5 at 1 Year) 0.9 (0.1 at 1 Year) 
  Characteristics Rate AHR, Death Rate AHR, Listing Rate AHR, Transplant 
Year of first 
dialysis 
  2001-2002 58.2 (1.2) 1 (Ref) 0.6 (0.1) 1 (Ref) 0.5 (0.1) 1 (Ref) 
 
  2003-2004 59.6 (1.2)a 1.04 (0.99-1.1)a 1.2 (0.2)b 1.75 (1.08-2.84)b 0.8 (0.1)a 1.43 (0.82-2.47)a 
 
  2005-2006 54.6 (1.1)b 0.95 (0.9-1.01)a 1.2 (0.2)b 1.75 (1.08-2.82)b 0.8 (0.1)a 1.36 (0.79-2.33)a 
 
  2007-2008 56.6 (1.3)a 0.97 (0.91-1.02)a 1.2 (0.2)b 1.77 (1.08-2.9)b 0.5 (0.1)a 0.87 (0.46-1.65)a 
 
  2009-2010 63.4 (1.7)b 1.06 (0.99-1.13)a 0.6 (0.2)a 0.91 (0.46-1.81)a 0.3 (0.1)a 0.54 (0.22-1.34)a 
Age, yrs.   < 40 18.6 (2) 1 (Ref) 5.8 (1.2) 1 (Ref) 3.2 (0.9) 1 (Ref) 
 
  40-64 40.8 (0.7) 2.15 (1.74-2.65) 1.5 (0.1) 0.27 (0.17-0.42) 1 (0.1) 0.29 (0.16-0.51) 
 
  ≥ 65 74.8 (0.9) 3.92 (3.19-4.83) 0.3 (0.1) 0.05 (0.03-0.09) 0.2 (0.1) 0.04 (0.02-0.09) 
Female sex Vs. Male 57.1 (0.8)a 0.97 (0.93-1)a 0.8 (0.1)b 0.78 (0.57-1.06)a 
 
0.5 (0.1)a 0.83 (0.56-1.22)a 
 
Race  White  54.7 (1.2) 1 (Ref) 0.7 (0.1) 1 (Ref) 0.4 (0.1) 1 (Ref) 
 
 Black 59.5 (0.6) 1.04 (0.99-1.09)a 1 (0.1)b 0.7 (0.37-1.34)a 0.7 (0.1)b 1.26 (0.46-3.44)a 
 
 Other 43.8 (2.6) 0.8 (0.7-0.9) 1.6 (0.6)b 0.42 (0.2-0.87)b 0.6 (0.4)a 0.55 (0.18-1.67)a 
Hispanic 
Ethnicity 
Yes Vs. No 49.3 (2) 0.92 (0.85-1)a 1.9 (0.4) 1.43 (0.91-2.24)a 
 
0.6 (0.3)a 0.66 (0.32-1.38)a 
 
Ischemic heart 
disease 
Yes Vs. No 73.1 (1.9) 1.11 (1.05-1.17) 0.4 (0.2)b 0.68 (0.34-1.34)a 
 
0.2 (0.1)b 0.46 (0.17-1.27)a 
 
Diabetes Yes Vs. No 66.7 (1.6) 1.13 (1.08-1.19) 0.6 (0.2)b 0.68 (0.41-1.13)a 0.4 (0.1)a 0.68 (0.35-1.3)a 
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Peritoneal 
Dialysis 
Vs. Hemodialysis 39.6 (2.3) 0.69 (0.61-0.77) 2.7 (0.6) 2.63 (1.62-4.27) 
 
1.5 (0.5)c 2.13 (1.13-4)b 
 
Access   Fistula 30.8 (2.6) 1 (Ref) 2.5 (0.8) 1 (Ref) 1.3 (0.6) 1 (Ref) 
 
  Graft 45.9 (5.2)c 1.45 (1.1-1.91)c 1.9 (1.3)a 0.96 (0.26-3.49)a 0.6 (1)a 0.53 (0.06-4.46)a 
 
  Catheter 60.1 (0.8) 2.12 (1.8-2.5) 0.9 (0.1)c 0.29 (0.15-0.55) 0.5 (0.1)b 0.26 (0.11-0.62)c 
Prior nephrology 
care ≤ 12 mo. 
Vs. > 12 mo. 58.8 (0.8) 1.38 (1.25-1.52) 1 (0.1)c 0.35 (0.21-0.6) 
 
0.5 (0.1)b 0.35 (0.17-0.71)c 
 
GFR > 15 
mL/min/1.73 m2 
Vs. ≤ 15 61 (2.5)a 1.07 (0.98-1.16)a 0.7 (0.3)a 0.72 (0.34-1.53)a 
 
0.2 (0.2)a 0.32 (0.08-1.28)a 
 
BMI, kg/m2   18.5-24.9 62.3 (0.9) 1 (Ref) 0.9 (0.1) 1 (Ref) 0.6 (0.1) 1 (Ref) 
 
  < 18.5 75.4 (3.2) 1.2 (1.1-1.31) 1 (0.4)a 1.25 (0.57-2.74)a 
 
0.3 (0.3)a 0.51 (0.12-2.12)a 
 
 
  25-29.9 54.7 (1) 0.9 (0.86-0.94) 0.9 (0.1)a 0.87 (0.6-1.26)a 0.6 (0.1)a 0.93 (0.59-1.46)a 
 
  ≥ 30 51.5 (1.1) 0.89 (0.85-0.94) 1.2 (0.2)a 1.17 (0.8-1.71)a 0.7 (0.1)a 1.08 (0.67-1.75)a 
Albumin, g/dL  ≥ 4 37.9 (1.4) 1 (Ref) 1.6 (0.3) 1 (Ref) 0.8 (0.2) 1 (Ref) 
 
3.5-3.9 48.9 (1.3) 1.21 (1.11-1.32) 1.3 (0.2)a 0.93 (0.56-1.52)a 
 
0.9 (0.2)a 1.32 (0.7-2.46)a 
 
 
< 3.5 64.7 (0.8) 1.57 (1.45-1.69) 0.8 (0.1)c 0.66 (0.43-1.01)a 
 
0.5 (0.1)b 0.71 (0.4-1.26)a 
 
Hemoglobin, 
g/dL 
  < 9 64 (1.1) 1 (Ref) 0.7 (0.1) 1 (Ref) 0.5 (0.1) 1 (Ref) 
   9-10.9 58 (0.9) 0.86 (0.83-0.9) 1 (0.1)b 1.74 (1.17-2.59)c 0.6 (0.1)a 1.49 (0.92-2.43)a 
   ≥ 11 48.3 (1.2) 0.71 (0.67-0.75) 1.4 (0.2) 2.34 (1.51-3.64) 1 (0.2)c 2.41 (1.42-4.08)c 
Region   Northeast 61.2 (1.3) 1 (Ref) 1.2 (0.2) 1 (Ref) 0.8 (0.2) 1 (Ref) 
 
  Midwest 54.4 (1.1) 0.9 (0.85-0.96) 1.2 (0.2)a 0.97 (0.65-1.46)a 1 (0.2)a 1.21 (0.75-1.96)a 
 
  South 59.2 (0.9)a 1.02 (0.97-1.08)a 0.6 (0.1) 0.42 (0.27-0.65) 0.3 (0.1)c 0.35 (0.19-0.63) 
  
  West 56.3 (1.3)c 0.98 (0.92-1.04)a 1.1 (0.2)a 0.75 (0.48-1.16)a 0.5 (0.1)a 0.52 (0.28-
0.98)b 
Parameter estimates are presented with either standard errors or 95% confidence intervals in parentheses. Rates are expressed per 100 
person-years. Hazards ratios for non-occurrence of listing and transplant were calculated as the inverse of the corresponding estimate for 
event occurrence. P values < 0.001 unless otherwise stated. AHR, adjusted (for age, sex, race, ethnicity) hazards ratio; BMI, body mass 
index; GFR, glomerular filtration rate; MM, Multiple Myeloma. a P value ≥ 0.05; b 0.01 ≤ P value < 0.05;  c 0.001 ≤ P value < 0.01
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Table 4. Event Ratios for Death and Graft Loss in Patients with MM (n =109).  
  Characteristics at 
Transplant (%) 
Outcomes After Transplant (%) 
Transplant Year   2001-02 11.9 Graft loss % 13.8 
 
  2003-04 10.1  % at 1 yr. 4.6 
 
  2005-06 27.5  Rate 4.2 (1.2)a 
 
  2007-08 26.6  AHR (Vs. 
Non MM) 
1.6 (1-2.7)a 
 
  2009-10 23.9 Death % 20.2 
Donor   Living 59.6  % at 1 yr. 6.4 
 
  Deceased 40.4  Rate 6.1 (1.4)c 
Years on dialysis 
  ≤ 1 16.5  AHR (Vs. 
Non MM) 
1.6 (1-2.4)b 
 
  > 1 83.5 Graft loss or death % 26.2 
Age at transplant, yrs.   < 40 9.2  % at 1 yr. 10.1 
 
  40-64 73.4  Rate 8.4 (1.6)b 
 
  ≥ 65 17.4  AHR (Vs. 
Non MM) 
1.6 (1-2.4)b 
Female Sex  38.5    
Race Black 12.8    
 
White 83.5    
 
Other 3.7    
Hispanic ethnicity  7.3    
Ischemic heart disease  3.7    
Diabetes  9.2    
Region   Northeast 25.9    
 
  Midwest 41.7    
 
  South 17.6    
    West 14.8       
Note: Parameter estimates are presented with standard errors or 95% confidence intervals in 
parentheses. Rates are expressed per 100 person-years. P values ≥ 0.05 throughout.  
AHR, adjusted (for age, sex, race, ethnicity) hazards ratio; BMI, body mass index; GFR, 
glomerular filtration rate; MM, multiple myeloma or light chain deposition disease. 
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Figure 1. County-level incidence rates, per million, of dialysis-requiring patients with Multiple 
Myeloma in 2001-2002 (upper panel) and 2009-2010 (lower panel). Incidence rate categories are 
quartiles of counties with non-zero incidence rates in 2001-2002. 
 
 
 		
Inc idenc e 0-4.6 4.7-8.6 8.7-17.4 >	17.4
Inc idenc e 0-4.6 4.7-8.6 8.7-17.4 >	17.4
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Figure 2. Outcome rates per 100 person-years in patients with Multiple Myeloma (n = 12,704, 
97.4%) and an equal number of matched control patients without MM. Factors used for matching 
were: biennium of dialysis initiation (2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-
2010); age (in 5-year increments until 84, ≥ 85); sex (male, female); race/ethnicity (non-Hispanic 
black, non-Hispanic white, Hispanic, other). Ref groups for statistical comparisons: biennium 
2001-2002; age < 40 years; non-Hispanic black race/ethnicity; northeast region.  
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*P < 0.05 for within-subgroup comparison between patients with and without MM. 
†P < 0.05 for between-subgroup comparison among patients with MM. 
§P < 0.05 for between-subgroup comparison among patients without MM. 	 	
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